Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRIO NASDAQ:FEMY NASDAQ:OSRH NASDAQ:TNON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$0.70+1.3%$0.70$0.50▼$1.55$30.90M1.55288,158 shs4,508 shsFEMYFemasys$0.87-1.8%$0.94$0.69▼$1.80$28.69M-2.56265,983 shs28,322 shsOSRHOSR$1.10+4.1%$1.30$1.00▼$13.40$21.28M1.562.19 million shs78,542 shsTNONTenon Medical$1.07+1.4%$1.03$0.85▼$15.79$8.12M1.222.52 million shs24,392 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth0.00%-4.59%-0.58%-6.03%-42.83%FEMYFemasys0.00%-4.84%+3.53%-26.67%-19.27%OSRHOSR0.00%-10.17%-31.17%-20.30%+105,999,900.00%TNONTenon Medical0.00%+3.43%+16.77%-5.80%+62.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRIODarioHealth1.3596 of 5 stars3.30.00.00.00.60.81.3FEMYFemasys2.4669 of 5 stars3.53.00.00.00.62.50.6OSRHOSRN/AN/AN/AN/AN/AN/AN/AN/ATNONTenon Medical1.5108 of 5 stars3.53.00.00.01.10.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRIODarioHealth 2.67Moderate Buy$2.00187.77% UpsideFEMYFemasys 3.00Buy$8.67898.46% UpsideOSRHOSR 0.00N/AN/AN/ATNONTenon Medical 3.00Buy$4.67336.14% UpsideCurrent Analyst Ratings BreakdownLatest TNON, DRIO, FEMY, and OSRH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/19/2025DRIODarioHealthLitchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.005/14/2025TNONTenon MedicalCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRIODarioHealth$28.03M1.10N/AN/A$2.11 per share0.33FEMYFemasys$1.63M17.32N/AN/A$0.10 per share8.68OSRHOSRN/AN/AN/AN/A($3.87) per shareN/ATNONTenon Medical$3.28M2.48N/AN/A$0.71 per share1.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRIODarioHealth-$42.75M-$0.56N/AN/AN/A-159.80%-65.81%-38.41%8/6/2025 (Estimated)FEMYFemasys-$18.82M-$0.91N/AN/AN/A-1,242.06%-392.45%-137.15%8/14/2025 (Estimated)OSRHOSR-$2.41MN/A0.00∞N/AN/A-36.89%-19.14%N/ATNONTenon Medical-$13.67M-$27.23N/A∞N/A-417.57%-558.92%-129.73%8/12/2025 (Estimated)Latest TNON, DRIO, FEMY, and OSRH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DRIODarioHealth-$0.11N/AN/AN/A$6.91 millionN/A8/14/2025N/AFEMYFemasys-$0.18N/AN/AN/AN/AN/A8/12/2025Q2 2025TNONTenon Medical-$0.47N/AN/AN/A$0.91 millionN/A5/20/2025Q1 2025OSRHOSRN/A-$1.04N/A-$1.04N/A$0.76 million5/14/2025Q1 2025DRIODarioHealth-$0.07-$0.14-$0.07-$0.14$7.48 million$6.75 million5/13/2025Q1 2025TNONTenon Medical-$1.06-$1.01+$0.05-$1.01$0.76 million$0.73 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRIODarioHealthN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/ATNONTenon MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRIODarioHealth0.262.011.77FEMYFemasys0.020.930.54OSRHOSRN/A0.250.20TNONTenon MedicalN/A5.465.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRIODarioHealth33.39%FEMYFemasys65.27%OSRHOSR55.30%TNONTenon Medical22.74%Insider OwnershipCompanyInsider OwnershipDRIODarioHealth11.20%FEMYFemasys11.54%OSRHOSR33.67%TNONTenon Medical0.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRIODarioHealth20044.46 million39.48 millionOptionableFEMYFemasys3032.53 million28.77 millionNot OptionableOSRHOSRN/A19.28 million12.79 millionN/ATNONTenon Medical87.59 million7.57 millionNot OptionableTNON, DRIO, FEMY, and OSRH HeadlinesRecent News About These CompaniesTenon Medical (NASDAQ:TNON) Trading Down 1% - Time to Sell?July 16, 2025 | americanbankingnews.comNASDAQ:TNON Financials | Tenon Medical Inc - Investing.comJuly 11, 2025 | investing.comTenon Medical Inc News (TNON) - Investing.comJuly 9, 2025 | investing.comTNON | Tenon Medical Inc. Annual Cash Flow Statement - MarketWatchJuly 4, 2025 | marketwatch.comTenon Medical Announces Initial Case Series Utilizing Catamaran(R) SI Joint Fusion System to Enhance Stabilization of the SI Joint for Patients Undergoing Lumbar FusionJune 12, 2025 | accessnewswire.comATenon Medical, Inc.: Tenon Medical Reports First Quarter 2025 Financial ResultsMay 14, 2025 | finanznachrichten.deTenon Medical, Inc.: Tenon Medical Reports First Quarter 2025 Financial ResultsMay 14, 2025 | finanznachrichten.deTenon Medical, Inc. (TNON) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comTenon Medical Reports First Quarter 2025 Financial ResultsMay 13, 2025 | accessnewswire.comATenon Medical, Inc. Announces Timing of First Quarter 2025 Financial ResultsApril 29, 2025 | accessnewswire.comAAlliance Global Partners Initiates Coverage of Tenon Medical (TNON) with Buy RecommendationApril 10, 2025 | msn.comTenon Medical initiated with a Buy at Alliance Global PartnersApril 9, 2025 | markets.businessinsider.comTenon Medical files to sell 5.67M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comTenon gets FDA clearance for Catamaran SI Joint Fusion System indicationMarch 26, 2025 | markets.businessinsider.comTenon Medical prices $2.5M registered direct offering at $2.00March 26, 2025 | markets.businessinsider.comFDA clears Tenon Medical’s Catamaran system expansionMarch 26, 2025 | investing.comTenon Medical dips 6%, prices $2.5M direct offeringMarch 26, 2025 | msn.comTenon Medical earns expanded indication for SI joint fusion systemMarch 25, 2025 | beckersspine.comBTenon Medical Shares Jump After FDA Clears Joint Drug for Broader UseMarch 25, 2025 | marketwatch.comTenon Medical, Inc. Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesMarch 25, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNON, DRIO, FEMY, and OSRH Company DescriptionsDarioHealth NASDAQ:DRIO$0.70 +0.01 (+1.31%) As of 10:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Femasys NASDAQ:FEMY$0.87 -0.02 (-1.80%) As of 10:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.OSR NASDAQ:OSRH$1.10 +0.04 (+4.13%) As of 09:58 AM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Tenon Medical NASDAQ:TNON$1.07 +0.02 (+1.42%) As of 10:12 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tenon Medical, Inc., a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
